Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight Report 2018-2024 - ResearchAndMarkets.com

DUBLIN--()--The "Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024 report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy. Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market.

Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024 Report highlights:

  • Clinical Insight on 70 Tubulin Inhibitors in pipeline
  • Dosage & Price Analysis of 10 Commercialized Drugs
  • Patent Approval, Expiry Year & Market Sales Indicators
  • Patent Analysis of Key Drugs
  • Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase
  • Future Perspective of Cancer Tubulin Inhibitors

Key Topics Covered:

1. Microtubules - Moving Target in Cancer Therapy

2. Mechanism of Action & Mechanism of Resistance of Tubulin Inhibitors

3. Microtubules & Their Role in Cellular Stress in Cancer

4. Prognostic Role of Tubulin for Prediction of Cancer Aggressiveness

5. Price & Dosage Analysis of Tubulin Inhibitor Drugs

6. Market Analysis of Tubulin Inhibitors

7. Global Cancer Tubulin Inhibitors Clinical Pipeline Overview

8. Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase

9. Marketed Cancer Tubulin Inhibitors Clinical Insight

10. Global Cancer Tubulin Inhibitors Market Dynamics

11. Future Perspective of Cancer Tubulin Inhibitors

12. Competitive Landscape

  • Abraxis Biosciences
  • Agensys
  • Amgen
  • Celgene
  • Eagle Pharmaceuticals
  • Endocyte
  • Genentech
  • Immunogen
  • Modra Pharmaceuticals
  • Pierre Fabre
  • Roche
  • Sanofi-Aventis
  • Seattle Genetics
  • Tocris Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/hr774n/global_cancer?w=4.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials